Now halfway through ISP, I start the third week at Novartis, where I will spend the next two weeks. This week I am shadowing Abhijit Agarwal, Franchise Lead of Scientific Engagement & Communications in Global Medical Affairs in the Cell & Gene Therapies department. 717 more words
The FDA Approved a Promising New Drug to Treat Migraines. Now, the Drugmakers' Stock Prices Are Rising
The stock prices of Amgen and Novartis have popped after the pharmaceutical companies won U.S. approval for a new drug that treats migraines.
Aimovig is a monthly shot that’s the first in a new class of anti-migraine treatments, coming at a cost of $6,900 per year without insurance. 186 more words
The FDA Is Naming and Shaming Companies Accused of Blocking Cheap Generic Drugs
The Food and Drug Administration (FDA) is taking what, for an agency that’s generally known for its caution and under-the-radar regulatory approach, may be seen as an aggressive new tact against drug makers: Publicly calling out companies accused of… 273 more words
What I'm Reading Today
A lot of news today with the ASCO Abstracts being released. I will leave the interpretation of the abstracts to people that are much more qualified to discuss them than I: 58 more words
The Fixer for Trump, Fixed Himself
Could anyone forget Trump’s promise to drain the swamp?
Nothing is more illustrative of the corruption that defines the swamp than payments/bribes to people who have political influence. 336 more words
Top Novartis Lawyer Exits Over the $1.2 Million It Paid to Trump Lawyer Michael Cohen
The top lawyer at Swiss pharmaceuticals giant Novartis has fallen on his sword over the company’s payments to U.S. President Donald Trump’s personal lawyer, Michael Cohen. 372 more words
